The Myeloproliferative Neoplasms Channel is supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
SOHO 2026 | Optimizing MPN treatment strategies in community practice
Aaron Gerds, MD, Cleveland Clinic, Cleveland, OH, discusses practical strategies for optimizing MPN treatment in community practice. He highlights the importance of reassessing JAK inhibitor therapy at key timepoints in myelofibrosis and considering a switch when response is inadequate, while noting interferons as an alternative to hydroxyurea in essential thrombocythemia and polycythemia vera. This interview took place at the 14th Annual Meeting of the Society of Hematologic Oncology (SOHO 2026) in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
